TABLE 1.
Baseline Characteristics
| Parameter | Total (n = 93) | Undetectable Total S Antibody; ≤ 0.8 (n = 46) | Detectable Total S Antibody; >0.8 (n = 47) | p |
|---|---|---|---|---|
| Antinucleocapsid antibody ≤ 1 | 48 (52) | 37 (80) | 11 (23) | < 0.001 |
| Age, median (IQR) | 59.0 (47.0–67.0) | 60.5 (50.0–69.5) | 55.0 (45.0–65.5) | 0.27 |
| Male, n (%) | 66 (71) | 32 (70) | 34 (72) | 0.95 |
| Body mass index, kg/m2, median (IQR) | 27.2 (23.9–33.1) | 27.3 (23.6–34.1) | 27.2 (24.4–31.6) | 0.20 |
| Time PCR to V1, median (IQR) | 1.0 (0.0–4.0) | 1.0 (0.0–2.0) | 1.0 (0.0–4.0) | 0.32 |
| Race, n (%) | ||||
| American Indian | 5 (5) | 3 (7) | 2 (4) | 0.10 |
| Asian | 13 (14) | 6 (13) | 7 (15) | |
| Black/African American | 16 (17) | 12 (26) | 4 (9) | |
| Pacific Islander | 1 (1) | 1 (2) | 0 (0) | |
| White | 56 (60) | 23 (50) | 33 (70) | |
| Unknown | 2 (2) | 1 (2) | 1 (2) | |
| Ethnicity, n (%) | ||||
| Hispanic/LatinX | 34 (37) | 11 (24) | 23 (49) | 0.92 |
| Comorbidities, n (%) | ||||
| Asthma | 9 (10) | 7 (15) | 2 (4) | 0.15 |
| Chronic kidney disease | 20 (22) | 11 (24) | 9 (19) | 0.76 |
| Diabetes mellitus | 30 (32) | 15 (33) | 15 (32) | 0.99 |
| Hypertension | 9 (10) | 3 (7) | 6 (13) | 0.50 |
| Alcohol abuse | 16 (17) | 9 (20) | 7 (15) | 0.75 |
| Cerebrovascular disease | 10 (11) | 6 (13) | 4 (9) | 0.71 |
| Coronary artery disease | 12 (13) | 6 (13) | 6 (13) | 0.99 |
| Active solid cancer | 7 (8) | 4 (9) | 3 (6) | 0.98 |
| Lymphoma | 1 (1) | 0 (0) | 1 (2) | 0.99 |
| Leukemia | 1 (1) | 0 (0) | 1 (2) | 0.99 |
| Solid organ transplant | 4 (4) | 1 (2) | 3 (6) | 0.62 |
| HIV | 3 (3) | 2 (4) | 1 (2) | 0.98 |
| Cirrhosis | 9 (10) | 3 (7) | 6 (13) | 0.50 |
| 8-Point Ordinal Scale Score, n (%) | ||||
| 4 (hospitalization) | 19 (20) | 10 (22) | 9 (19) | 0.92 |
| 5 (any supplemental oxygen) | 20 (22) | 10 (22) | 10 (21) | |
| 6 (high-flow nasal cannula or noninvasive positive pressure ventilation) | 33 (35) | 15 (33) | 18 (38) | |
| 7 (invasive mechanical ventilation or ECMO) | 21 (23) | 11 (24) | 10 (21) | |
| Acute Physiology and Chronic Health Evaluation II, median (IQR) | 22.0 (15.0–28.0) | 22.0 (18.0–28.8) | 22.0 (13.5–26.5) | 0.27 |
| Treatments during hospitalization, n (%) | ||||
| Corticosteroids | 57 (61) | 30 (65) | 27 (57) | 0.58 |
| Remdesivir | 52 (56) | 28 (61) | 24 (51) | 0.46 |
| Tocilizumab | 4 (4) | 0 (0) | 4 (9) | 0.13 |
ECMO = extracorporeal membrane oxygenation, IQR = interquartile range, PCR = polymerase chain reaction.